A recent study suggests that a GLP-1 drug, liraglutide, may protect the brains of people with mild Alzheimer’s disease, slowing cognitive decline by 18% over one year. This effect is likely due to the drug’s ability to reduce brain inflammation, improve insulin resistance, and lower the impact of Alzheimer’s biomarkers.
